| Entry |
|
|---|
| Name |
Tobramycin (JP18/USP);
Tobi (TN);
Tobracin (TN);
Tobrex (TN);
Bethkis (TN) |
|---|
| Product |
|
|---|
| Generic |
TOBRAMYCIN (A-S Medication Solutions), TOBRAMYCIN (A-S Medication Solutions), TOBRAMYCIN (Advanced Rx Pharmacy of Tennessee), TOBRAMYCIN (American Health Packaging), TOBRAMYCIN (Amneal Pharmaceuticals LLC), TOBRAMYCIN (Ascend Laboratories), TOBRAMYCIN (Asclemed USA), TOBRAMYCIN (Asclemed USA), TOBRAMYCIN (Aurobindo Pharma Limited), TOBRAMYCIN (Bausch & Lomb Incorporated), TOBRAMYCIN (Belcher Pharmaceuticals), TOBRAMYCIN (DirectRX), TOBRAMYCIN (Genericus), TOBRAMYCIN (Gland Pharma Limited), TOBRAMYCIN (Lifestar Pharma LLC), TOBRAMYCIN (Lifestar Pharma LLC), TOBRAMYCIN (Lupin Pharmaceuticals), TOBRAMYCIN (Medsource Pharmaceuticals), TOBRAMYCIN (Micro Labs Limited), TOBRAMYCIN (NorthStar RxLLC), TOBRAMYCIN (NorthStar RxLLC), TOBRAMYCIN (NuCare Pharmaceuticals), TOBRAMYCIN (NuCare Pharmaceuticals), TOBRAMYCIN (Preferred Pharmaceuticals), TOBRAMYCIN (Preferred Pharmaceuticals), TOBRAMYCIN (Proficient Rx LP), TOBRAMYCIN (Proficient Rx LP), TOBRAMYCIN (Proficient Rx LP), TOBRAMYCIN (Proficient Rx LP), TOBRAMYCIN (Quality Care Products), TOBRAMYCIN (REMEDYREPACK), TOBRAMYCIN (REMEDYREPACK), TOBRAMYCIN (RPK Pharmaceuticals), TOBRAMYCIN (RPK Pharmaceuticals), TOBRAMYCIN (Redpharm Drug), TOBRAMYCIN (Redpharm Drug), TOBRAMYCIN (Sandoz), TOBRAMYCIN (Slate Run Pharmaceuticals), TOBRAMYCIN (Somerset Therapeutics), TOBRAMYCIN (Sun Pharmaceutical Industries), TOBRAMYCIN (Teva Pharmaceuticals USA), TOBRAMYCIN (Teva Pharmaceuticals USA), TOBRAMYCIN INHALATION (Prasco), TOBRAMYCIN INHALATION SOLUTION (Dr. Reddy's Laboratories), TOBRAMYCIN INHALATION SOLUTION (NorthStar RxLLC), TOBRAMYCIN OPHTHALMIC SOLUTION (Alembic Pharmaceuticals Limited), TOBRAMYCIN OPHTHALMIC SOLUTION (Alembic Pharmaceuticals) |
|---|
| Formula |
C18H37N5O9
|
|---|
| Exact mass |
467.2591
|
|---|
| Mol weight |
467.51
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Source |
Streptomyces tenebrarius [TAX: 1933]
|
|---|
| Class |
Antibacterial
DG01447 Aminoglycoside antibiotic
|
|---|
| Remark |
| Product (DG00608): | D00063<JP/US> D02542<US> |
| Product (mixture): | D11178<US> D12133<US> |
|
|---|
| Efficacy |
Antibacterial, Protein biosynthesis inhibitor |
|---|
| Disease |
Cystic fibrosis patients with Pseudomonas aeruginosa [DS: H00218] |
|---|
| Target |
50S ribosomal subunit
30S ribosomal subunit |
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Biosynthesis |
| map00524 | Neomycin, kanamycin and gentamicin biosynthesis |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J01 ANTIBACTERIALS FOR SYSTEMIC USE
J01G AMINOGLYCOSIDE ANTIBACTERIALS
J01GB Other aminoglycosides
J01GB01 Tobramycin
D00063 Tobramycin (JP18/USP) <JP/US>
S SENSORY ORGANS
S01 OPHTHALMOLOGICALS
S01A ANTIINFECTIVES
S01AA Antibiotics
S01AA12 Tobramycin
D00063 Tobramycin (JP18/USP) <JP/US>
USP drug classification [BR:br08302]
Antibacterials
Aminoglycosides
Tobramycin
D00063 Tobramycin (JP18/USP)
Ophthalmic Agents
Ophthalmic Anti-Infectives
Antibacterials, Ophthalmic
Tobramycin
D00063 Tobramycin (JP18/USP)
Respiratory Tract/Pulmonary Agents
Cystic Fibrosis Agents
Inhaled Anti-infectives
Tobramycin
D00063 Tobramycin (JP18/USP)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
13 Agents affecting sensory organs
131 Ophthalmic agents
1317 Ophthalmic antibiotics
D00063 Tobramycin (JP18/USP)
6 Agents against pathologic organisms and parasites
61 Antibiotics
612 Acting mainly on gram-negative bacteria
6123 Amino sugars
D00063 Tobramycin (JP18/USP)
Drug groups [BR:br08330]
Antibacterial
DG01447 Aminoglycoside antibiotic
DG00608 Tobramycin
D00063 Tobramycin
Drug classes [BR:br08332]
Antibacterial
DG01447 Aminoglycoside antibiotic
D00063 Tobramycin
Antimicrobials [BR:br08307]
Antibacterials
Protein biosynthesis inhibitor
Aminoglycoside
D00063 Tobramycin (JP18/USP) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00063 Tobramycin
D00063 Tobramycin injection
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00063
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D00063
Drug groups [BR:br08330]
Antibacterial
DG01447 Aminoglycoside antibiotic
DG00608 Tobramycin
Antimicrobials abbreviations [BR:br08327]
Antibacterials
Protein biosynthesis inhibitor
Aminoglycoside
DG00608 Tobramycin
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 32
1 C1y C 20.6560 -20.0968
2 C1y C 20.6560 -21.4973
3 C1y C 21.8689 -22.1975
4 C1y C 23.0818 -21.4973
5 C1y C 23.0818 -20.0968
6 O2x O 21.8689 -19.3965
7 C1b C 19.4432 -19.3965
8 O1a O 18.2473 -20.0872
9 O1a O 19.4432 -22.1975
10 N1a N 21.8689 -23.5978
11 O1a O 24.3134 -22.2085
12 O2a O 24.3134 -19.3855
13 C1y C 25.4878 -18.6963
14 C1y C 26.7056 -19.3879
15 C1x C 27.9134 -18.6791
16 C1y C 27.9035 -17.2786
17 C1y C 26.6857 -16.5869
18 C1y C 25.4779 -17.2958
19 N1a N 26.7157 -20.7965
20 N1a N 29.0779 -16.5893
21 O1a O 24.2675 -16.6084
22 O2a O 26.6757 -15.1950
23 C1y C 27.8854 -14.4851
24 O2x O 29.0946 -15.1718
25 C1y C 30.3025 -14.4631
26 C1y C 30.2926 -13.0626
27 C1x C 29.0835 -12.3758
28 C1y C 27.8755 -13.0846
29 C1b C 31.5468 -15.1693
30 N1a N 31.5569 -16.5953
31 O1a O 31.5060 -12.3503
32 N1a N 26.6567 -12.3923
BOND 34
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 5 6 1
6 1 6 1
7 1 7 1 #Up
8 7 8 1
9 2 9 1 #Down
10 3 10 1 #Up
11 4 11 1 #Down
12 5 12 1 #Down
13 13 12 1 #Down
14 13 14 1
15 14 15 1
16 15 16 1
17 16 17 1
18 17 18 1
19 13 18 1
20 14 19 1 #Up
21 16 20 1 #Up
22 18 21 1 #Up
23 17 22 1 #Down
24 23 22 1 #Down
25 23 24 1
26 24 25 1
27 25 26 1
28 26 27 1
29 27 28 1
30 23 28 1
31 25 29 1 #Up
32 29 30 1
33 26 31 1 #Down
34 28 32 1 #Down
|
|---|
|
